Funding for this research was provided by:
Merck KGaA Darmstadt, Germany
Text and Data Mining valid from 2018-05-07
Received: 13 November 2017
Revised: 24 February 2018
Accepted: 9 March 2018
First Online: 7 May 2018
Compliance with ethical standards
: The scientific guarantor of this publication is Melvin D’Anastasi.
: The authors of this manuscript declare relationships with the following companies: Merck KGaA Darmstadt, Germany.In addition:J.W. Holch:Julian Walter Holch served on advisory board for Roche, has received honoraria from Roche and travel support from NovartisN. Hesse:Merck KGaAA.B. Baumann:Merck KGaAD.P. Modest:Honoraria: Merck, Amgen, Roche, BMS, MSD, Servier, SirtexTravel Support: Amgen, Merck, Roche, Bayer, BMSResearch Grant: Merck, Amgen, RocheS. Stintzing:Honoraria for talks and advisory board role from: AMGEN, Bayer, Lilly, Merck KgaA, Roche, Sanofi, TakedaV. Heinemann:Honoraria (myself): Merck, Amgen, Roche, Sanofi, SIRTEX, Servier Consulting or Advisory Board (myself): Merck, Amgen, Roche, Sanofi, SIRTEX, BMS; MSD, Novartis, Boehringer Ingelheim, Servier Research funding (my institution): Merck, Amgen, Roche, Sanofi, Pfizer, Boehringer Ingelheim, Sirtex, Bayer Travel accommodation expenses (myself): Merck, Roche, Amgen, SIRTEX, BayerW.H. Sommer:Founder Smart Reporting GmbH
: One of the authors has significant statistical expertise.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported in:OrderedList removed
: “Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial” (meanwhile published in European Journal of Radiology)
: • retrospective• multicentre study